{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-009306","form_type":"8-K","ticker":"EMED","cik":"0001715819","company_name":"Electromedical Technologies, Inc","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.282609+00:00","generated_at":"2026-06-20T03:56:53.100319+00:00","sec_items":["3.03","5.01","5.02","5.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEO Matthew Wolfson granted voting control via Series B preferred; authorized shares increased to 2B+","bullets":["Employment agreement gives Wolfson one Series B preferred share with voting control equal to all common shares plus 100k votes on fully diluted basis.","Wolfson retains $265k/yr CEO salary plus $100k/yr CFO salary; incentives include up to 25M common shares for annual growth and cash bonuses for quarterly growth.","Robert L. Hymers III appointed as independent director and compensation committee member for 6-month term; receives $5k monthly in common shares.","Charter amendment increases authorized capital to 2,000,000,001 shares (199M common, 1M Series A preferred, 1 Series B preferred); filed with Delaware."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-009306","json":"https://secwatch.observer/filing/0001104659-23-009306.json","markdown":"https://secwatch.observer/filing/0001104659-23-009306.md","text":"https://secwatch.observer/filing/0001104659-23-009306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/tm235211d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:56:53.100319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"acce1d0816","claim":"Robert L. Hymers III was appointed as Independent Director at Electromedical Technologies, Inc.","evidence_excerpt":"On February 1, 2023, effective January 1, 2023, the Company appointed Robert L. Hymers, III, age 39, as an independent director and member of the compensation committee of the Company for a term of six months.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"},{"claim_id":"c366e68c61c618b425718dd2a9eeffa953de38b9","claim":"Electromedical Technologies, Inc: Increased authorized shares to two billion and one, including Common Stock, Series A Preferred, and Series B Preferred; par value $0.00001 per share (effective 2023-01-31).","evidence_excerpt":"On January 31, 2023, the board of directors approved a resolution to amend the Company’s Certificate of Incorporation to: (1) increase the Company’s authorized shares to two billion and one shares of capital stock, including: one hundred and ninety-nine million shares designated as “Common Stock,” with a par value of $0.00001 per share; one million shares designated as “Series A Preferred Shares,” par value $0.00001 per share; and one share designated as “Series B Preferred Shares,” par value $0.00001 per share.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-31"}],"fact_type":"governance_change"},{"claim_id":"a28dc09086eca5583d3178aa5202cbf0c923dd2b","claim":"Electromedical Technologies, Inc underwent a change of control involving Matthew Wolfson (closed 2023-01-26).","evidence_excerpt":"Matthew Wolfson entered into an executive employment agreement. The Company agreed, as partial consideration","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1715819/000110465923009306/0001104659-23-009306-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Matthew Wolfson"},{"label":"Closing","value":"2023-01-26"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}